Table 2.
Trials employing autologous Stem cell transplant consolidation
| Regimen | Year | Author/institution | n | PFS/EFS | Remarks |
|---|---|---|---|---|---|
| Hyper-CVAD/MTX-Ara-C → Cy/TBI25 | 1998 | Khouri/MD Anderson | 45 | 3 yr EFS 42% Median PFS 39 mos | n = 25 1st line |
| Various26 | 2000 | Vose/Univ Nebraska | 40 | 2 year EFS 36% | |
| RIT/cy/etop27 | 2002 | Gopal/Univ WA Seattle | 16 | 3 year PFS 61% | All relapsed |
| Various23 | 2003 | Vandenberghe/EBBMT/ABMTR | 195 | 2 year PFS 55% 5 year PFS 33% | |
| CHOP like induction Dexa-BEAM → cy/TBI vs IFNα21 | 2005 | Dreyling/European MCL network | 62 (ASCT) | Median PFS 39 mos (ASCT) vs 17 mos (IFN) | First line |
| R-maxi-CHOP/HIDAC → BEAM28 | 2008 | Geisler/Nordic Lymphoma group | 160 | 6 year EFS 56% | First line |
| R-maxi-CHOP, eto, MTX/HIDAC → CEP, R7 | 2008 | Hsi/CALGB | 52 | 3 year PFS 52%, EFS 57% | Stratified by Ki-67 and PIM1 |
Abbreviations: Cy/TBI, cyclophosphamide/total body irradiation; RIT/cy/eto, radioimmunotherapy/cyclophosphamide/etoposide; HIDAC, high-dose cytarabine; BEAM, BCNU/etoposide/cytarabine/melphalan; CHOP, cyclophosphamide–doxorubicin–vincristine–prednisone; MTX, methotrexate; CEP, carmustine–etoposide–cyclophosphamide; mos, months; PFS, progression free survival; EFS, event free survival.